Neoantigen-based cancer vaccines represent new, truly personalized therapeutic …
JACKSONVILLE, Fla., June 27, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno …
Market Data Forecast recently published a report on the Global Cancer Vaccines Market which estimates the market …
The technology uses the body’s own T cells, which live within white blood cells, to …
Cancer in the cervix, which is the lower part of the uterus, is called cervical …
Jun 21, 2017 (Marketwired via COMTEX) -- BATON ROUGE, LA--(Marketwired - June 21, 2017) - OncBioMune Pharmaceuticals, Inc. (otcqb:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company …
Market Data Forecast recently published a report on the “Global Cancer Vaccines Market“which estimates the market to grow from USD 2.84 billion from 2016 to …
* TapImmune reaches 50% patient enrollment benchmark in phase 2 study of novel t-cell vaccine targeting triple …
Research and Markets has announced the addition of the "Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023" report to their offering. Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023 …